Please ensure Javascript is enabled for purposes of website accessibility

Could This Marijuana Stock Be Added to the S&P 500?

By Sean Williams – Apr 12, 2018 at 8:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pot stock in America's broad-based stock index? Yeah, it's a real possibility.

Though spring only recently arrived, marijuana stocks have been flowering for a good two years. Cannabis research firm ArcView has forecast a compound annual growth rate of 28% for the legal weed industry in North America through 2021, leading to what could amount to almost $25 billion in annual sales if these estimates prove accurate.

Growing from less than $7 billion in annual sales to almost $25 billion between 2016 and 2021 in North America would be one heck of a feat for an industry that's still illegal in every country except Uruguay. Of course, that could soon change. Canada appears to be on the verge of legalizing adult-use marijuana by this summer, paving the way for recreational cannabis sales to commence by August or September. This should add $5 billion or more in annual sales, assuming approval.

As a result of marijuana's expansion potential, pot stock valuations -- especially of Canadian growers -- have gone through the roof. There are a half-dozen marijuana stocks currently boasting a market cap north of $1 billion.

A jar of cannabis lying atop a small stack of cash.

Image source: Getty Images.

Could a weed stock actually be added to the iconic S&P 500?

This raises the question: Could we actually see a marijuana stock added to the broad-based, yet iconic, S&P 500 (^GSPC -1.51%). While I do believe the answer is "yes," I'd preface it with the caveat that five out of six of these billion-dollar pot stocks likely won't be eligible for addition.

Even though the components for the S&P 500 are selected by a committee, inclusion does require that a few liquidity and market cap requirements be met. These include:

  • A minimum market cap of $6.1 billion
  • Annual dollar value traded to float-adjusted market capitalization is greater than 1
  • Minimum monthly trading volume of 250,000 shares in each of the six months leading up to evaluation

Additionally, the committee excludes limited partnerships, master limited partnerships, over-the-counter (OTC)-listed stocks, exchange-traded funds, preferred stock, tracking stock, unit trusts, equity warrants, royalty trusts, and American depositary receipts (ADRs), to name a few securities that can't be added. It's also worth noting that while non-U.S. companies are eligible for inclusion, just 18 of the current 505 components are headquartered outside the United States. 

A stock trader looking at charts on his computer while on the phone.

Image source: Getty Images.

These marijuana stocks (currently) have no chance

Right off the bat, we can see an issue: the $6.1 billion minimum market cap requirement. There isn't a single marijuana stock currently at that level, meaning the prospects of inclusion in the S&P 500 in 2018 aren't looking great. But within a year or two that could change.

The bigger issue is that a number of the largest marijuana stocks by market cap aren't listed on the New York Stock Exchange or Nasdaq, as is required for inclusion in the S&P 500. Canopy Growth Corp., Aurora Cannabis, Aphria, and MedReleaf, all boast billion-dollar market caps, but also trade on the OTC exchange. For the time being, they have no chance of inclusion in the S&P 500.

An initial glance at cannabinoid-drug developer GW Pharmaceuticals (GWPH) might give you the impression that it could have a shot at inclusion in the future. It sports a $3.1 billion market cap, is listed on the Nasdaq, and has a potentially game-changing cannabidiol-based drug known as Epidiolex being reviewed by the Food and Drug Administration. Unfortunately, GW Pharmaceuticals is an ADR that's headquartered in the United Kingdom. This makes it ineligible for inclusion in the S&P 500.

This pot stock may one day be in the S&P 500

That leaves one billion-dollar pot stock as eligible for future inclusion in the S&P 500: Scotts Miracle-Gro (SMG -3.10%). With the exception of its market cap -- currently $4.8 billion -- Scotts Miracle-Gro easily meets all other inclusion requirements. In fact, it's currently larger than 13 of the 505 components in the index.

A hemp farmer pruning his crop.

Image source: Getty Images.

Scotts itself isn't a pure-play marijuana stock like the other companies mentioned above. In 2017, it generated 89% of its sales from its core lawn and garden operating segment, which tends to grow by a low-to-mid-single-digit percentage, is reliant on product innovation, and can be somewhat unpredictable thanks to changing weather patterns.

Where Scotts Miracle-Gro gets its association to cannabis is through its Hawthorne Gardening subsidiary, which comprised 11% of total sales last year. Hawthorne, which has primarily grown via acquisitions in recent years, is focused on hydroponics -- growing plants in a water solvent solution -- as well as lighting, soil, and nutrient solutions for the cannabis industry. In 2017, Hawthorne's sales grew 137% to $287.2 million, with operating profit tripling to $35.5 million. In terms of organic volume, Hawthorne saw a year-over-year increase of 20% in 2017. 

In its more recently reported first-quarter results, Hawthorne's total sales (not to be confused with organic growth) increased 20% from the year-ago quarter. In other words, Hawthorne Gardening is really driving Scotts at the moment, and could get even more fuel for the fire if Canada legalizes recreational cannabis. In terms of its bottom line, Wall Street has estimated a compound annual earnings growth rate of 14.6% for Scotts through 2021. 

While nothing is ever a given when it comes to the marijuana industry or committee selection for an index with as much importance as the S&P 500, I believe there does appear to be a path forward for Scotts Miracle-Gro to become the first marijuana stock to be added to the S&P 500 at some point within the next year or two.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Scotts Miracle-Gro Company Stock Quote
The Scotts Miracle-Gro Company
SMG
$42.75 (-3.10%) $-1.37
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,585.62 (-1.51%) $-54.85
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.